| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telomere | 41 | 2025 | 215 | 9.180 |
Why?
|
| Telomerase | 23 | 2023 | 160 | 4.900 |
Why?
|
| Dyskeratosis Congenita | 12 | 2022 | 19 | 3.160 |
Why?
|
| Saccharomyces cerevisiae Proteins | 12 | 2019 | 277 | 2.680 |
Why?
|
| Telomere-Binding Proteins | 11 | 2022 | 43 | 2.660 |
Why?
|
| Saccharomyces cerevisiae | 13 | 2019 | 426 | 2.630 |
Why?
|
| Anemia, Aplastic | 9 | 2025 | 59 | 2.090 |
Why?
|
| Telomere Shortening | 9 | 2022 | 33 | 1.920 |
Why?
|
| DNA-Binding Proteins | 14 | 2019 | 2048 | 1.840 |
Why?
|
| Telomere Homeostasis | 8 | 2024 | 43 | 1.750 |
Why?
|
| Germ-Line Mutation | 10 | 2025 | 333 | 1.720 |
Why?
|
| DNA End-Joining Repair | 5 | 2019 | 34 | 1.700 |
Why?
|
| Antigens, Nuclear | 7 | 2018 | 60 | 1.450 |
Why?
|
| Bone Marrow Diseases | 5 | 2023 | 41 | 1.320 |
Why?
|
| Intellectual Disability | 5 | 2022 | 1056 | 1.220 |
Why?
|
| Serine Proteases | 2 | 2021 | 7 | 1.190 |
Why?
|
| DNA Repair | 8 | 2023 | 585 | 1.140 |
Why?
|
| Microcephaly | 4 | 2021 | 331 | 1.140 |
Why?
|
| Fetal Growth Retardation | 3 | 2020 | 239 | 1.060 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 2 | 2018 | 6 | 1.040 |
Why?
|
| Mutation | 29 | 2024 | 5849 | 1.030 |
Why?
|
| Ku Autoantigen | 7 | 2018 | 21 | 1.000 |
Why?
|
| Mutation, Missense | 4 | 2019 | 875 | 0.870 |
Why?
|
| DNA, Circular | 1 | 2023 | 17 | 0.840 |
Why?
|
| Germ Cells | 2 | 2022 | 195 | 0.830 |
Why?
|
| DNA, Fungal | 4 | 2019 | 77 | 0.790 |
Why?
|
| Exoribonucleases | 2 | 2019 | 23 | 0.770 |
Why?
|
| DNA Damage | 4 | 2025 | 513 | 0.740 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2025 | 3160 | 0.740 |
Why?
|
| Mutagenesis, Insertional | 2 | 2019 | 144 | 0.720 |
Why?
|
| DNA Helicases | 4 | 2023 | 231 | 0.710 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2020 | 10 | 0.700 |
Why?
|
| Bone Marrow | 6 | 2021 | 325 | 0.680 |
Why?
|
| Ribosomal Proteins | 1 | 2020 | 71 | 0.680 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2025 | 724 | 0.640 |
Why?
|
| Pedigree | 8 | 2021 | 1607 | 0.640 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2022 | 34 | 0.620 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 227 | 0.600 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2024 | 138 | 0.590 |
Why?
|
| Child, Preschool | 26 | 2025 | 14030 | 0.560 |
Why?
|
| Humans | 79 | 2025 | 125392 | 0.560 |
Why?
|
| Cell Line | 6 | 2023 | 2756 | 0.560 |
Why?
|
| Protein Binding | 11 | 2018 | 1756 | 0.550 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 13 | 0.550 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2016 | 131 | 0.550 |
Why?
|
| Antibodies, Antinuclear | 1 | 2017 | 28 | 0.540 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2016 | 31 | 0.540 |
Why?
|
| Transaminases | 1 | 2017 | 32 | 0.540 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 40 | 0.530 |
Why?
|
| Inheritance Patterns | 2 | 2014 | 127 | 0.530 |
Why?
|
| Hepatitis | 1 | 2017 | 57 | 0.520 |
Why?
|
| Neoplasms | 5 | 2025 | 2792 | 0.520 |
Why?
|
| Calreticulin | 1 | 2016 | 20 | 0.520 |
Why?
|
| Thrombopoietin | 1 | 2016 | 32 | 0.510 |
Why?
|
| Thrombocythemia, Essential | 1 | 2016 | 30 | 0.510 |
Why?
|
| Janus Kinase 2 | 2 | 2016 | 132 | 0.490 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 779 | 0.470 |
Why?
|
| Tryptophan | 1 | 2015 | 91 | 0.470 |
Why?
|
| Cholestasis | 1 | 2017 | 154 | 0.470 |
Why?
|
| Lipomatosis | 1 | 2014 | 15 | 0.450 |
Why?
|
| Chromosomes, Fungal | 3 | 2011 | 49 | 0.450 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 209 | 0.440 |
Why?
|
| Siblings | 3 | 2014 | 198 | 0.440 |
Why?
|
| Adolescent | 26 | 2025 | 19373 | 0.420 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 42 | 0.410 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 285 | 0.400 |
Why?
|
| MicroRNAs | 1 | 2019 | 837 | 0.400 |
Why?
|
| Neutropenia | 3 | 2019 | 200 | 0.400 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 429 | 0.400 |
Why?
|
| Phenotype | 13 | 2024 | 4263 | 0.390 |
Why?
|
| Hematologic Diseases | 2 | 2023 | 79 | 0.370 |
Why?
|
| Cellular Senescence | 2 | 2010 | 161 | 0.360 |
Why?
|
| Syndrome | 5 | 2023 | 1121 | 0.360 |
Why?
|
| Female | 38 | 2025 | 66885 | 0.360 |
Why?
|
| Recombination, Genetic | 5 | 2013 | 447 | 0.360 |
Why?
|
| Child | 30 | 2025 | 24436 | 0.360 |
Why?
|
| Cell Cycle Proteins | 4 | 2020 | 656 | 0.360 |
Why?
|
| Male | 36 | 2025 | 61663 | 0.350 |
Why?
|
| Pancytopenia | 2 | 2023 | 41 | 0.340 |
Why?
|
| Penetrance | 2 | 2020 | 102 | 0.330 |
Why?
|
| Genomic Instability | 3 | 2022 | 229 | 0.310 |
Why?
|
| Proteins | 1 | 2014 | 1036 | 0.310 |
Why?
|
| Genetic Variation | 3 | 2020 | 1502 | 0.300 |
Why?
|
| Exodeoxyribonucleases | 2 | 2009 | 51 | 0.300 |
Why?
|
| Chromosome Disorders | 1 | 2010 | 311 | 0.300 |
Why?
|
| Amino Acid Sequence | 5 | 2020 | 2714 | 0.300 |
Why?
|
| Alleles | 7 | 2022 | 1615 | 0.300 |
Why?
|
| Hematopoiesis | 2 | 2021 | 216 | 0.290 |
Why?
|
| Leukemia, Myeloid | 2 | 2019 | 85 | 0.290 |
Why?
|
| DNA Replication | 3 | 2023 | 352 | 0.290 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1527 | 0.280 |
Why?
|
| Models, Theoretical | 1 | 2009 | 364 | 0.280 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2025 | 96 | 0.270 |
Why?
|
| Arteriovenous Fistula | 2 | 2018 | 57 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1251 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2024 | 558 | 0.270 |
Why?
|
| Protein Structure, Tertiary | 4 | 2020 | 767 | 0.260 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2020 | 553 | 0.250 |
Why?
|
| Pulmonary Veins | 2 | 2018 | 161 | 0.250 |
Why?
|
| Immunoprecipitation | 2 | 2019 | 198 | 0.240 |
Why?
|
| Ethosuximide | 1 | 2025 | 14 | 0.240 |
Why?
|
| Primary Myelofibrosis | 2 | 2018 | 51 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 535 | 0.240 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2025 | 44 | 0.240 |
Why?
|
| Infant | 15 | 2022 | 12518 | 0.230 |
Why?
|
| Pulmonary Artery | 2 | 2018 | 443 | 0.220 |
Why?
|
| Young Adult | 11 | 2024 | 9069 | 0.220 |
Why?
|
| Silent Information Regulator Proteins, Saccharomyces cerevisiae | 4 | 2017 | 9 | 0.220 |
Why?
|
| DNA | 2 | 2014 | 1609 | 0.220 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2018 | 209 | 0.220 |
Why?
|
| Adult | 19 | 2025 | 29692 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 651 | 0.210 |
Why?
|
| Osteochondrodysplasias | 2 | 2019 | 66 | 0.210 |
Why?
|
| HeLa Cells | 3 | 2023 | 806 | 0.210 |
Why?
|
| DNA Ligases | 1 | 2002 | 17 | 0.200 |
Why?
|
| Gene Order | 2 | 2014 | 79 | 0.200 |
Why?
|
| Hydroxyurea | 1 | 2023 | 82 | 0.200 |
Why?
|
| Biology | 1 | 2022 | 29 | 0.200 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 193 | 0.190 |
Why?
|
| Inflammation | 2 | 2020 | 1446 | 0.190 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 1216 | 0.190 |
Why?
|
| Cell Division | 2 | 2003 | 781 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2025 | 384 | 0.190 |
Why?
|
| GATA2 Transcription Factor | 1 | 2021 | 39 | 0.190 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 362 | 0.190 |
Why?
|
| Aging | 2 | 2022 | 1182 | 0.190 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 2021 | 7 | 0.190 |
Why?
|
| Galactosemias | 1 | 2021 | 14 | 0.180 |
Why?
|
| Antilymphocyte Serum | 2 | 2019 | 56 | 0.180 |
Why?
|
| Leukoplakia, Oral | 1 | 2021 | 4 | 0.180 |
Why?
|
| Receptor, EphB2 | 1 | 2021 | 8 | 0.180 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 27 | 0.180 |
Why?
|
| Nails | 1 | 2021 | 20 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2025 | 2314 | 0.180 |
Why?
|
| Central Nervous System Cysts | 1 | 2020 | 11 | 0.180 |
Why?
|
| Cyclosporine | 2 | 2019 | 147 | 0.180 |
Why?
|
| Anemia, Macrocytic | 1 | 2020 | 8 | 0.180 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2020 | 8 | 0.180 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2021 | 46 | 0.180 |
Why?
|
| Riboflavin Deficiency | 1 | 2020 | 9 | 0.180 |
Why?
|
| Dimerization | 3 | 2007 | 144 | 0.170 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2019 | 236 | 0.170 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 3892 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 2 | 2020 | 575 | 0.170 |
Why?
|
| Riboflavin | 1 | 2020 | 38 | 0.170 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2020 | 54 | 0.170 |
Why?
|
| Muscle Spasticity | 1 | 2020 | 73 | 0.170 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 59 | 0.170 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 39 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 618 | 0.160 |
Why?
|
| Gene Deletion | 2 | 2021 | 789 | 0.160 |
Why?
|
| Calcinosis | 1 | 2020 | 179 | 0.160 |
Why?
|
| Nuclear Proteins | 5 | 2021 | 1265 | 0.150 |
Why?
|
| Ataxia | 1 | 2020 | 170 | 0.150 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 57 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 143 | 0.150 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.150 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 2018 | 7 | 0.150 |
Why?
|
| Telangiectasis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 188 | 0.150 |
Why?
|
| Biological Variation, Population | 1 | 2018 | 24 | 0.150 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 71 | 0.150 |
Why?
|
| Arthralgia | 1 | 2018 | 56 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 2020 | 172 | 0.150 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 66 | 0.150 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 117 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 122 | 0.150 |
Why?
|
| Metabolome | 1 | 2020 | 293 | 0.150 |
Why?
|
| Phosphorylation | 2 | 2020 | 1631 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 794 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2021 | 541 | 0.140 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 20 | 0.140 |
Why?
|
| Molecular Docking Simulation | 1 | 2017 | 110 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 157 | 0.140 |
Why?
|
| Retina | 1 | 2020 | 450 | 0.140 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 120 | 0.140 |
Why?
|
| Models, Molecular | 2 | 2013 | 1080 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 271 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2019 | 699 | 0.140 |
Why?
|
| Protein Isoforms | 1 | 2018 | 403 | 0.140 |
Why?
|
| Hypergammaglobulinemia | 1 | 2017 | 11 | 0.140 |
Why?
|
| Acute Disease | 2 | 2017 | 1111 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 320 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 700 | 0.130 |
Why?
|
| NF-kappa B | 1 | 2019 | 459 | 0.130 |
Why?
|
| Transcription Factors | 3 | 2023 | 2593 | 0.130 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 46 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 292 | 0.130 |
Why?
|
| Liver Failure | 1 | 2017 | 89 | 0.130 |
Why?
|
| Androgens | 1 | 2018 | 279 | 0.130 |
Why?
|
| Platelet Count | 1 | 2016 | 138 | 0.130 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 254 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2024 | 1039 | 0.120 |
Why?
|
| Family | 2 | 2016 | 567 | 0.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 72 | 0.120 |
Why?
|
| Quinolinic Acid | 1 | 2015 | 10 | 0.120 |
Why?
|
| Amino Acid Transport Systems | 1 | 2015 | 8 | 0.120 |
Why?
|
| Seizures | 1 | 2020 | 872 | 0.120 |
Why?
|
| Amino Acid Substitution | 2 | 2020 | 399 | 0.120 |
Why?
|
| NAD | 1 | 2015 | 45 | 0.120 |
Why?
|
| Galactose | 1 | 2015 | 54 | 0.120 |
Why?
|
| Fatal Outcome | 2 | 2018 | 359 | 0.120 |
Why?
|
| Patients | 1 | 2016 | 120 | 0.120 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 181 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2017 | 797 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 1756 | 0.120 |
Why?
|
| Bleomycin | 1 | 2015 | 154 | 0.120 |
Why?
|
| Prognosis | 6 | 2020 | 4648 | 0.120 |
Why?
|
| Leprosy, Tuberculoid | 1 | 2014 | 7 | 0.120 |
Why?
|
| Molluscum Contagiosum | 1 | 2014 | 11 | 0.110 |
Why?
|
| Actins | 1 | 2017 | 346 | 0.110 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2014 | 13 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 576 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 537 | 0.110 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 166 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 368 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 205 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2014 | 89 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 168 | 0.110 |
Why?
|
| Enzyme Activation | 1 | 2015 | 627 | 0.110 |
Why?
|
| Neutrophils | 1 | 2016 | 381 | 0.110 |
Why?
|
| Granuloma | 1 | 2014 | 68 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16389 | 0.110 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2014 | 106 | 0.110 |
Why?
|
| Abdomen | 1 | 2014 | 127 | 0.110 |
Why?
|
| Models, Biological | 3 | 2009 | 1461 | 0.110 |
Why?
|
| Animals | 9 | 2021 | 34241 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2013 | 128 | 0.100 |
Why?
|
| Infant, Newborn | 4 | 2020 | 8240 | 0.100 |
Why?
|
| Threonine | 1 | 2012 | 60 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2013 | 285 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 140 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 276 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 2640 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 572 | 0.100 |
Why?
|
| Middle Aged | 9 | 2025 | 26990 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 329 | 0.100 |
Why?
|
| Serine | 1 | 2012 | 175 | 0.100 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 50 | 0.090 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2011 | 3 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 472 | 0.090 |
Why?
|
| Glutamine | 1 | 2012 | 215 | 0.090 |
Why?
|
| Base Sequence | 3 | 2011 | 3103 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 519 | 0.090 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 59 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 547 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2021 | 4536 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 319 | 0.090 |
Why?
|
| HLA Antigens | 2 | 2022 | 245 | 0.090 |
Why?
|
| Genes, Dominant | 1 | 2011 | 245 | 0.090 |
Why?
|
| Mice | 6 | 2021 | 17637 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1273 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 296 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2010 | 59 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 33 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 51 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 492 | 0.080 |
Why?
|
| Leukemia | 2 | 2012 | 373 | 0.080 |
Why?
|
| Saccharomyces | 1 | 2009 | 12 | 0.080 |
Why?
|
| Werner Syndrome Helicase | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2009 | 617 | 0.080 |
Why?
|
| Receptors, Transferrin | 1 | 2009 | 10 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 20 | 0.080 |
Why?
|
| Liver | 1 | 2017 | 1749 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2009 | 55 | 0.080 |
Why?
|
| Chromosome Segregation | 1 | 2009 | 63 | 0.080 |
Why?
|
| Fibrosarcoma | 1 | 2009 | 26 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2010 | 157 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2014 | 941 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 30 | 0.080 |
Why?
|
| Genes, Essential | 1 | 2009 | 40 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2009 | 95 | 0.080 |
Why?
|
| RecQ Helicases | 1 | 2009 | 62 | 0.080 |
Why?
|
| Fungal Proteins | 1 | 2009 | 134 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 100 | 0.080 |
Why?
|
| Plasmids | 2 | 2014 | 513 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2009 | 134 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 55 | 0.070 |
Why?
|
| Exome | 3 | 2018 | 1034 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 735 | 0.070 |
Why?
|
| North America | 2 | 2021 | 242 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 5185 | 0.070 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2007 | 57 | 0.070 |
Why?
|
| Cell Survival | 1 | 2009 | 814 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2008 | 142 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2007 | 70 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 120 | 0.070 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 238 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1203 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 582 | 0.070 |
Why?
|
| Genes, cdc | 1 | 2006 | 25 | 0.060 |
Why?
|
| Gene Expression | 1 | 2011 | 1560 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 186 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 651 | 0.060 |
Why?
|
| Hair Diseases | 1 | 2005 | 14 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2007 | 398 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 581 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2022 | 4824 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2005 | 113 | 0.060 |
Why?
|
| Translocation, Genetic | 2 | 2021 | 358 | 0.060 |
Why?
|
| Genotype | 2 | 2017 | 2568 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2008 | 329 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2004 | 48 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2004 | 85 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2024 | 173 | 0.050 |
Why?
|
| Yeasts | 1 | 2003 | 43 | 0.050 |
Why?
|
| Protein Structure, Quaternary | 1 | 2003 | 98 | 0.050 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2023 | 1 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1244 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2003 | 167 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2024 | 12412 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 760 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3746 | 0.050 |
Why?
|
| DNA Ligase ATP | 1 | 2002 | 11 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2003 | 291 | 0.050 |
Why?
|
| HLA-B Antigens | 1 | 2022 | 28 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 550 | 0.050 |
Why?
|
| Genetic Counseling | 2 | 2016 | 223 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 658 | 0.050 |
Why?
|
| Binding Sites | 3 | 2017 | 1304 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 97 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2917 | 0.050 |
Why?
|
| Cell Self Renewal | 1 | 2021 | 43 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2021 | 135 | 0.050 |
Why?
|
| Fetal Hemoglobin | 1 | 2021 | 28 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2003 | 834 | 0.050 |
Why?
|
| Glycolipids | 1 | 2021 | 32 | 0.050 |
Why?
|
| Megakaryocytes | 1 | 2021 | 42 | 0.050 |
Why?
|
| Biomarkers | 1 | 2010 | 3096 | 0.050 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2021 | 35 | 0.040 |
Why?
|
| Leukocytes | 2 | 2017 | 212 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 126 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 880 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1899 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2020 | 43 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 140 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2020 | 61 | 0.040 |
Why?
|
| Ribosomes | 1 | 2021 | 137 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 112 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2020 | 82 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2024 | 368 | 0.040 |
Why?
|
| Genomics | 2 | 2019 | 1499 | 0.040 |
Why?
|
| Heterozygote | 2 | 2014 | 672 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2019 | 1010 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 152 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2020 | 384 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 418 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 280 | 0.040 |
Why?
|
| Risk Factors | 1 | 2013 | 10331 | 0.040 |
Why?
|
| Eukaryotic Cells | 1 | 1998 | 32 | 0.040 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2018 | 16 | 0.040 |
Why?
|
| De Lange Syndrome | 1 | 2018 | 44 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2014 | 1328 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 87 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 292 | 0.040 |
Why?
|
| Consanguinity | 1 | 2018 | 115 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 125 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 351 | 0.040 |
Why?
|
| Education | 1 | 2018 | 109 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2019 | 3056 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 272 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 762 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2017 | 66 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 265 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 339 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 726 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 379 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1397 | 0.030 |
Why?
|
| Apoptosis | 1 | 2003 | 1806 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 300 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 71 | 0.030 |
Why?
|
| Perfusion | 1 | 2017 | 207 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 529 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 118 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 614 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 778 | 0.030 |
Why?
|
| Hypoxia | 1 | 2017 | 250 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 22 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 547 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1240 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 888 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1329 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 570 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1996 | 189 | 0.030 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2014 | 54 | 0.030 |
Why?
|
| Sumoylation | 1 | 2014 | 37 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1058 | 0.030 |
Why?
|
| Aged | 3 | 2016 | 19896 | 0.030 |
Why?
|
| Lysine | 1 | 2014 | 196 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2018 | 1022 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 702 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 190 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1361 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2894 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 763 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2012 | 200 | 0.020 |
Why?
|
| Anemia, Myelophthisic | 1 | 2012 | 2 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 14 | 0.020 |
Why?
|
| Reticulin | 1 | 2012 | 8 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 543 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 4396 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2058 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 960 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2012 | 69 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2012 | 33 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 73 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 584 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 187 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 818 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 949 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 299 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2012 | 101 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2467 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 320 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 595 | 0.020 |
Why?
|
| Spores, Fungal | 1 | 2009 | 14 | 0.020 |
Why?
|
| Sirtuin 2 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2009 | 49 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2009 | 66 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 50 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2009 | 93 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 289 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 228 | 0.020 |
Why?
|
| Lung | 1 | 2017 | 1496 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2433 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 193 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 158 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1496 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 418 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2009 | 453 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2009 | 287 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 810 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3589 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1290 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 417 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1078 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1987 | 199 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1693 | 0.020 |
Why?
|
| RNA, Ribosomal, 5.8S | 1 | 2005 | 6 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 2077 | 0.020 |
Why?
|
| Cartilage | 1 | 2005 | 48 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2005 | 50 | 0.020 |
Why?
|
| RNA Stability | 1 | 2005 | 84 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6607 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 503 | 0.010 |
Why?
|
| Embryonic Development | 1 | 2005 | 214 | 0.010 |
Why?
|
| United States | 1 | 2019 | 10936 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2005 | 663 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 3350 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1005 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3075 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 1289 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1711 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1996 | 150 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1996 | 104 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1996 | 100 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1996 | 230 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1987 | 369 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1987 | 480 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1987 | 1699 | 0.000 |
Why?
|